Medline ® Abstract for Reference 52
of 'Medical treatment for relapsed epithelial ovarian, fallopian tubal, or peritoneal cancer: Platinum-sensitive disease'
PARP inhibitors for targeted treatment in ovarian cancer.
Lancet. 2017;390(10106):1929. Epub 2017 Sep 12.
Women's Cancers, Lifespan Cancer Institute, Medical Oncology, Rhode Island Hospital, Medicine, Alpert Medical School of Brown University, Providence, RI 02903, USA. Electronic address: don.dizon@Lifespan.org.